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Abstract Fractalkine is the only as yet known member of a
novel class of chemokines. Besides its novel Cys-X-X-X-Cys
motif, fractalkine exhibits features which have not been described
for any other member of the chemokine family, including its
unusual size (397 amino acids human, 395 mouse) and the
possession of a transmembrane anchor, from which a soluble
form may be released by extracellular cleavage. This report
demonstrates the abundant mRNA and fractalkine protein
expression in neuronal cells. The neuronal expression of
fractalkine mRNA is unaffected by experimentally induced
inflammation of central nervous tissue.
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1. Introduction
Chemokines are small secreted proteins that stimulate the
directional migration of leukocytes and mediate in£ammation
[1]. Most recently, a novel subclass of chemokines, the
N-chemokines, was de¢ned, characterised by a Cys-X-X-X-
Cys motif [2,3]. So far the only member of this subclass is
fractalkine [2]. The murine homologue of human fractalkine
was subsequently published by another group and termed
neurotactin [3]. Fractalkine exists possibly in two forms: (i)
as a type 1 membrane protein furnished with a transmem-
brane anchor and a cytoplasmic domain and (ii) as a shed
glycoprotein of 95 kDa. Both reports demonstrated the
chemotactic activity of the shed protein on leukocytes [2,3].
An orphan G-protein-coupled 7-transmembrane receptor
-V28- [4] was identi¢ed to be a speci¢c receptor for fractalkine
and is now termed CX3CR1 [5,6]. Bazan et al. underlined the
potential role of fractalkine as an adhesion molecule in leu-
kocyte tra⁄cking at the endothelium and demonstrated that
the expression of fractalkine can be induced in cultured hu-
man umbilical vein endothelial cells by IL-1L and TNF-K [2].
An immunohistochemical analysis on mouse brain sections
reported by Pan et al. [3] implied that microglial cells are
the major cellular source of fractalkine in the brain and that
protein expression is upregulated by lipopolysaccharide treat-
ment as well as in experimentally induced allergic encepha-
lomyelitis (EAE). This report demonstrates that neuronal cells
are the major source of fractalkine biosynthesis in the central
nervous system (CNS). Using rat and mouse models of EAE,
we show that the high abundance of fractalkine mRNA in
neuronal cells and the plasticity of expression are not a¡ected
by EAE brain in£ammation. Immunohistochemical analysis
of human and monkey CNS tissues shows a prominent neuro-
nal staining for fractalkine.
2. Materials and methods
2.1. Models of experimental autoimmune encephalomyelitis
Myelin oligodendrocyte glycoprotein (MOG)-speci¢c T cell lines
were derived from Dark Agouti (Harlan Winkelmann, Germany)
rats immunised with a synthetic peptide corresponding to the immu-
nodominant T-cell epitope of MOG (amino acids 93^110; EG-
GYTCFFRDHSYQEEAA) [7]. EAE was induced in naive female
recipients (115^150 g) using a dose of 5U106 freshly activated T
cell blasts. The cells were injected intraperitoneally in a volume of
1 ml culture medium. EAE was induced in female SJL/J mice (Harlan
Winkelmann, Germany) by active immunisation with recombinant rat
MOG as described previously [8]. Disease was scored on the following
scale: 0.5, partial loss of tail tone; 1, complete tail atony; 2, hind limb
weakness; 3, hind limb paralysis; 4, moribund; 5, dead.
2.2. Radioactive and non-radioactive in situ hybridisation
For in situ hybridisation, 14 Wm thick tissue sections were cut from
frozen brains, ¢xed in phosphate-bu¡ered formaldehyde and proc-
essed as previously described [9]. 35S-Labeled cRNA was transcribed
from a 396 bp subfragment of rat fractalkine (EMBL Nucleotide
Sequence Database accession number Y16813) in antisense and sense
orientation. A mouse fractalkine cDNA template of 948 bp was am-
pli¢ed by RT-PCR from total brain mRNA using the following
primer set derived from the published sequence [3] : 5P CTG CCG
GGT CAG CAC CTC GGC ATG 3P and 5P CCT TGT GGC
TGC CTG GGT GTC GGG 3P. Sequence analysis revealed full iden-
tity with the published nucleotide sequence. 35S-Labeled cRNA was
transcribed from this fragment in antisense and sense orientation.
After application of speci¢c 35S riboprobes radioactive signals were
detected by autoradiography on Hyper¢lm L-max (Amersham) (expo-
sure time 2 days) or coating sections with Kodak NTB-2 nuclear
emulsion [10]. For visualisation of non-radioactive hybrids the dig-
oxigenin detection method (Boehringer, Mannheim, Germany) was
applied [9]. Dark- and bright¢eld analysis was performed with an
AX70 microscope (Olympus).
2.3. Immunohistochemistry
Immunohistochemistry for fractalkine was carried out on depara⁄-
nised tissue sections using an antigen retrieval technique [10] (10 min
cooking in 10 mM Na-citrate bu¡er, pH 6.0 at 95‡C) and the standard
avidin-biotin-peroxidase complex technique. Light microscopic immu-
nohistochemistry was performed on depara⁄nised sections of Bouin
Hollande ¢xed tissue as described previously [10].
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Fig. 1. Species-speci¢c fractalkine antisense cRNA probes were hybridised to cryostat sections of normal rat brain (A) and EAE rat brain (B,
clinical stage 3.7) as well as normal mouse brain (G) and EAE in£amed mouse brain (H). X-ray ¢lm analysis reveals that fractalkine mRNA is
abundantly expressed in many brain regions with high concentrations of neurones (A, B) and (G, H). Comparing sections from normal rat
brains (A) and EAE rat brains (B) as well as normal mouse brains (G) and EAE mouse brains (H), no di¡erence in the distribution pattern of
fractalkine mRNA is seen. EAE brain in£ammation was monitored on consecutive sections using the expression of mRNA coding for the
B-chain of rat C1q as a marker for microglial activation as previously described [14]. In non-in£amed brain tissue C1q mRNA is expressed at
low abundance (D) whereas C1q mRNA levels are markedly higher in (E), a consecutive section of the EAE in£amed brain hybridised in par-
allel with fractalkine antisense cRNA (B). No hybridisation signals were obtained with rat fractalkine (C) and mouse fractalkine cRNA probes
transcribed in sense orientation (I). A consecutive section of the EAE mouse brain shown in (H) was hybridised with a mouse C1q B-chain
speci¢c 35S-labeled cRNA transcribed from a 247 bp long 5P-speci¢c BamHI cDNA subfragment [16] in antisense orientation (J).
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2.4. Northern blot analysis
Approximately 15 Wg of total RNA isolated by cesium chloride
density centrifugation was separated, blotted to a nylon membrane
(for method see [11]) and subsequently hybridised with random
primed (Boehringer, Mannheim, Germany) [32P]dCTP (Amersham)-
labeled cDNA probes for rat fractalkine and the rat B-chain for C1q
[11]. Variations in the loading of total RNA were determined by
hybridisation with an oligonucleotide speci¢c for the 28S rRNA
[12]. The hybridisation signals obtained were quanti¢ed by laser den-
sitometry of the autoradiographs using an Ultroscan XL Enhanced
Laser Densitometer from Pharmacia Biosystems (Uppsala, Sweden)
and normalised against the 28S rRNA abundance (not shown).
3. Results and discussion
To assess whether fractalkine mRNA expression could
serve as a marker for microglial cells or even microglial acti-
vation, we isolated cDNAs speci¢c for rat and mouse fractal-
kine for in situ hybridisation and Northern blot analyses of
normal and EAE mouse and rat brains [7,8,13]. The results
were consistent in both animal models: Fig. 1A depicts frac-
talkine mRNA expression on a cryostat section of a normal
rat brain in comparison to a rat brain with full-blown EAE
(Fig. 1B), and the sense control (Fig. 1C). Likewise, no di¡er-
ence in mRNA abundance and the plasticity of expression can
be observed between normal mouse brain (Fig. 1G) and EAE
in£amed mouse brain (Fig. 1H). Fractalkine mRNA is ex-
pressed in brain grey matter with predominance to areas
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Fig. 2. Using a non-radioactive in situ hybridisation technique frac-
talkine mRNA was seen in the neuronal layers II and III of piri-
form cortex (A). Note the absence of any positive labeling in layer I
(A) where cell bodies of macro- and microglia predominate. High
resolution micrographs of non-radioactive (B) and radioactive (C) in
situ hybridisation demonstrate neuronal perikarya labeled for frac-
talkine mRNA in the layer III of piriform cortex (B) and in the
deep layers of parietal cortex (C) while the cells in the white matter
of the corpus callosum (cc in C) lack positive labeling. Exposure
times of autoradiographs 3 weeks (C); size bars: 200 Wm (A), 50 Wm
(B,C).
Fig. 3. Total RNA preparations from normal and EAE brains were
analysed by Northern blotting and hybridised subsequently with
32P-labeled cDNA probes for rat fractalkine (A) and the rat B-chain
for C1q (B, [11]). The latter hybridisation allowed us to monitor the
degree of EAE brain in£ammation over the time course of EAE in-
duction with animals 7 and 8 on day 2 after T-cell transfer, animals
5 and 6 on day 3 (clinical stage 2), animals 3 and 4 on day 4 (clini-
cal stage 3.2 and 3.4) and animals 1 and 2 on day 5 (clinical stage
3.5 and 3.3 respectively). The 28S rRNA hybridisation signals used
to normalise the loading of total RNA are shown in (C).
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with high concentration of neurones such as the neocortex
and the hippocampal formation and is virtually absent from
white matter.
High resolution in situ hybridisation revealed localisation of
fractalkine mRNA in neuronal cell bodies with no obvious
expression in glial or endothelial cells (Fig. 2A^C). These in
vivo results are supported by the detection of fractalkine
mRNA in the human neuroblastoma cell lines LAN-1 and
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Fig. 4. Immunohistochemistry shows that fractalkine immunoreactivity is present in neuronal cell bodies of rhesus monkey neocortex (A) and
in motoneurones and nerve ¢bres of the ventral human spinal cord (C). The absence of staining in preabsorption controls with excess recombi-
nant fractalkine protein on consecutive sections demonstrates the speci¢city of the neuronal immunostaining. Size bar: 200 Wm.
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IMR-32 (not shown). EAE did not a¡ect the neuronal pattern
of expression or the abundance of fractalkine mRNA as
shown in Fig. 1B. The latter observation was con¢rmed by
the Northern blot results shown in Fig. 3A. In all brains,
fractalkine mRNA was highly expressed and no di¡erences
in the intensity of hybridisation signals were observed between
normal (lane 9) and brains at di¡erent stages of EAE (lanes
8^1). The same blot was rehybridised with a cDNA probe for
the B-chain of rat C1q [11] to verify the course and degree of
EAE in£ammation in these animals (Fig. 3B) as the severity
of disease is paralleled by a dramatic increase in C1q mRNA
abundance [14].
Using a polyclonal antibody raised against the recombinant
chemokine domain of human fractalkine, it is shown that also
fractalkine immunoreactivity is predominant in neurones of
rhesus monkey neocortex (Fig. 4A) and in motoneurones of
human spinal cord (Fig. 4C).
The ¢nding of a constitutive and abundant neuronal
mRNA expression for fractalkine is in agreement with two
recently published reports [15,16]. This contribution, however,
demonstrates for the ¢rst time that (i) fractalkine protein is
predominantly expressed in neuronal cells (on human and
monkey CNS tissues) and that (ii) fractalkine mRNA abun-
dance in rat and mouse brain tissues is una¡ected by EAE
brain in£ammation.
These results favour the view of more general physiological
functions of fractalkine such as the mediation of adhesion and
cell-cell communication between neurones and CX3CR1 bear-
ing cells occurring also in the total absence of pro-in£amma-
tory conditions.
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